Product/Composition:- | Osimertinib Tablets |
---|---|
Strength:- | 40 mg, 80 mg |
Form:- | Oral Tablets |
Reference Brands:- | Tagrisso® (US & EU) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Osimertinib Tablets (brand name Tagrisso®) are used to treat EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. As a third-generation tyrosine kinase inhibitor (TKI), Osimertinib selectively targets EGFR mutations. Available in 40 mg and 80 mg strengths, it is a reliable solution for oncology treatment in US and EU markets, manufactured under GMP standards.
Osimertinib Tablets are a third-generation tyrosine kinase inhibitor (TKI) used in the treatment of EGFR-mutant non-small cell lung cancer (NSCLC), including T790M resistance mutations. Marketed under the brand name Tagrisso®, Osimertinib selectively targets and inhibits EGFR mutations, providing a more precise treatment for metastatic NSCLC. Available in 40 mg and 80 mg tablet strengths, Osimertinib offers significant benefits in advanced lung cancer care. Manufactured under GMP-compliant conditions, it is an effective and reliable solution for US and EU pharmaceutical distributors looking to provide cutting-edge oncology treatments in precision medicine.
Embrace a platform that empowers you to invest in gold online effortlessly, making the path to financial growth accessible to everyone.
Get access to the finest pharmacy products with a NazarethPharmacy.com. They offer comprehensive worldwide pharmacy services, making them your best choice for online medications